which led to two members of the committee resigning in protest.

The clinical trials used to justify its approval do not show practical impact clinically (i.e. patient's don't show clinical improvement or a reduced rate of decline), its cost, and the nature of Medicare and Medicaid being required to reimburse for the drug makes it dangerous for the solvency of these programs and worsening the level of health care spending.